Can Globus Medical Stock Rally 30% After This Dip?

Globus Medical (GMED) shares fell 19.1% since November 4, 2026, after lowering its 2026 revenue forecast. Historically, the stock has rallied a median 39.3% within a year after similar drops. Revenue declined 0.7% in Q3 2026, with full-year revenue forecast cut to $3.09B. Management expects new products to drive growth in 2027.

Original reporting
Published Nov 17, 2026, 2:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Can Globus Medical Stock Rally 30% After This Dip? — source image
Decision brief

The 30-second read

$GMEDNeutralLow
01

Why it matters

It argues a potential rebound depends on whether new spine products like SCRIPT begin adding to sales, while current guidance points to no meaningful growth contribution until 2027 and a mid-single-digit Q4 sales decline.

02

Market read

For traders, the actionable takeaway is the guidance-driven growth delay and the February 2027 earnings catalyst for U.S. Spine growth, rather than a near-term event.

03

What to watch

The piece emphasizes SCRIPT timing, but it does not quantify competitive dynamics, reimbursement changes, or whether Nevro revenue decline is stabilizing, all of which could affect the next earnings read-through.

Relevance 4/10Novelty 4/10Timing: into the next earnings window, expected February 2027

Background

The article frames GMED’s post-November selloff as a pattern of sharp dips followed by mixed one-year outcomes, then ties the current dip to lowered 2026 revenue guidance and delayed spine product contribution.

Company-level read

Ticker impact

$GMEDNeutralMedium confidence
Context

Globus Medical shares are down 19.1% since Nov. 4 after it lowered its 2026 revenue forecast and said SCRIPT spine launches won’t add meaningful growth until 2027.

Expected impact

Likely choppy trading with downside risk until the next earnings update clarifies U.S. Spine growth and any early traction from SCRIPT.

Evidence & confidence

The article’s decision-relevant inputs are the lowered 2026 revenue forecast, the delayed growth timing for SCRIPT into 2027, and the upcoming February 2027 reporting window for U.S. Spine growth.

Market effects

Highlights execution risk in spine device product cycles, where delayed launches can reset growth expectations for medtech peers.

No clear regional spillover beyond U.S. spine revenue focus.

Limited, as the catalysts described are company-specific product and guidance timing.

Counterpoint

Even with stalled sales growth, improving operating margin and cash flow could support valuation and reduce downside if investors re-rate profitability durability.

Key entities

  • Globus Medical

    Subject of the article, with lowered 2026 revenue forecast and delayed growth contribution from SCRIPT into 2027.

  • SCRIPT

    Patient-specific spine implant line management says will not add meaningful growth until 2027.

  • Nevro

    Pain-treatment company acquired by Globus Medical; revenue fell 25.7% in the quarter cited.

Related articles

$GMEDHighAI 8/10

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after reporting Q3 2026 revenue of $763.7M, below estimates, and lowering full-year revenue guidance to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program.

$GMEDHighAI 8/10

Globus Medical Inc (GMED) Q3 2026 Earnings Call Highlights: Revenue Miss, Nevro Weakness

Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, missing expectations and lowering full-year guidance to $3.09B. Nevro revenue declined 25.7% YoY, and US Spine growth slowed. Despite this, free cash flow reached a record $225M, and gross margins expanded to 69.5%. The company expects 2027 growth from new products and market expansion, with mid- to high-single-digit revenue growth targeted.

$GMEDMedAI 8/10

Globus Medical Q3 Earnings Call Highlights

Globus Medical (GMED) reported Q3 earnings with GAAP net income of $141.2M and adjusted net income of $167M. The company expects a mid-single-digit revenue decline in Q4 due to delayed product launches and slower recovery at Nevro. Nevro's revenue fell 9% sequentially, but adjusted EBITDA margin improved to 19.9%. Globus plans to launch a new implantable pulse generator in 2027 and completed two small acquisitions. Operating cash flow rose 6% to $265M, and free cash flow increased 5% to $225M.

$GMEDHigh

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after Q3 2026 revenue of $763.7M missed estimates and full-year guidance was lowered to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program. The stock is down 17.7% YTD.

$GMEDHighAI 8/10

Why is Globus Medical stock plunging today?

Globus Medical (GMED) stock fell 12.5% to $71.26, a 52-week low, after Q3 2026 revenue missed estimates at $763.7M, down 0.7% YoY. The company cut full-year revenue guidance to $3.09B. Analysts downgraded the stock, citing weak growth outlook and insider selling. The S&P 500 and Nasdaq rose, but GMED underperformed.